Tirzepatide Savings Card: What Actually Cuts Your Bill in 2026

Is there a real tirzepatide savings card — and how much does it actually cut your bill?

Yes, but it belongs to the brand, not the molecule. Eli Lilly runs a Zepbound Savings Card that can bring a fill down to $25, and a separate Mounjaro Savings Card that does the same thing for its diabetes brand. Both work the same basic way: you enroll online, activate the card, and use it at the pharmacy counter or through your LillyDirect prescription. Neither is insurance, and Lilly can change or end either program at any time — worth remembering given how often these terms shift.

On the Zepbound card specifically, eligible patients pay as little as $25 for a one-, two-, or three-month fill, with Lilly's contribution capped at $100, $200, or $300 a month depending on the fill length, and $1,300 total for the calendar year. You get up to 13 fills a year on the card, and the current version expires December 31, 2026 — Lilly has renewed these programs annually, so expect a fresh version to appear around January if you're reading this later in the year.

Who actually qualifies for the Zepbound Savings Card

The card only works if two things are both true: you have commercial insurance, and that plan covers Zepbound as a benefit, even partially. A high deductible or a prior-authorization requirement doesn't disqualify you — the coverage itself is the gate. If your insurer has no Zepbound benefit at all, the card has nothing to attach to, and you'll want the self-pay pricing further down this page instead.

• Qualifies: commercially insured, plan covers Zepbound (even with a copay or coinsurance), 18 or older, US or Puerto Rico resident.
• Does not qualify: Medicare (all parts), Medicare Advantage, Medigap, Medicaid, TRICARE, VA, or DoD coverage — a standard federal restriction on manufacturer coupons.
• Also excluded: any commercial plan that flatly excludes Zepbound from its formulary, since there's no covered benefit for the card to discount.

One thing worth knowing if you're on Medicare: separate from this manufacturer card, a CMS pilot has been floated for mid-2026 that would let some Medicare Part D beneficiaries access Zepbound at a roughly $50-a-month copay. That's a government program, not the Lilly coupon, and its details were still firming up as of this writing — ask your Part D plan directly rather than assuming it applies.

Zepbound coupon vs. Mounjaro coupon: the mix-up that costs women money

Zepbound and Mounjaro are the same molecule — tirzepatide — made by the same company, sold under two names because the FDA approved it for two different uses. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. That split carries straight through to the coupons: they are two separate programs with two separate rule sets, and you cannot use one to discount the other.

The Mounjaro Savings Card mirrors the Zepbound card's $25-per-fill structure, but the caps are different — up to $150, $300, or $450 a month depending on fill length, with a $1,950 annual maximum — and, critically, it's restricted to a prescription written for Mounjaro's FDA-approved use. That means a Mounjaro prescription for off-label weight loss, which some prescribers still write when a patient's insurance won't touch Zepbound, sits outside what the card is designed to cover.

• Zepbound Savings Card: for Zepbound prescriptions, weight-management indication, up to $1,300/yr in savings.
• Mounjaro Savings Card: for Mounjaro prescriptions written for type 2 diabetes specifically, up to $1,950/yr in savings.
• Neither card transfers to the other brand or to an off-label use of either one — the FDA-approved indication on your prescription is what the program checks against.

If your goal is weight management and your insurance won't cover Zepbound, the honest options are the Zepbound self-pay pricing below, or a conversation with your prescriber about whether you have a genuine, documented type 2 diabetes diagnosis that would make Mounjaro — and its coupon — appropriate on its own medical merits, not as a workaround.

No insurance, or the card just doesn't apply — LillyDirect's self-pay vials

For everyone the savings card leaves out — uninsured patients, or anyone whose plan simply doesn't cover Zepbound — Lilly's own self-pay program through LillyDirect is the next-best official price. It sells Zepbound as single-dose vials, not the pre-filled pen, and that format is exactly what makes the lower price possible.

The tiers run $299 a month for the 2.5mg starter dose, $399 for 5mg, and $449 for the 7.5mg-through-15mg range — all FDA-approved medication shipped directly from Lilly. The one rule to build a calendar reminder around: you have to refill within 45 days of your last delivery to keep that pricing. Miss the window and the higher doses reset to $499-$699 a month, a jump of 40% or more.

Does GoodRx actually help — and can you stack it with the savings card?

It's worth checking, but temper expectations. GoodRx is known for cutting generic prices dramatically, and a lot of women assume it will do the same here. It doesn't, in general, because Zepbound and Mounjaro are still under patent, and Lilly's contracts with the pharmacy-benefit middlemen behind discount cards leave little room for a real cut. A recent pricing check found GoodRx running roughly $995 to $1,050 a month for Zepbound and $990 to $1,100 for Mounjaro — close to full retail — though that figure is notably higher than GoodRx pricing reported on other pages of this site checked a few weeks earlier, so treat the exact number as unconfirmed until you look it up directly for your ZIP code.

And no, you can't stack it with anything. GoodRx is a cash-price coupon; you use it instead of insurance, not alongside it, and it can't be combined with the manufacturer savings card either. If your plan covers Zepbound at all, the savings card will almost always beat GoodRx by a wide margin. GoodRx earns its place here as a fallback to price-check against LillyDirect, not as a first move.

Free samples, trial offers, and the patient-assistance question

There's no free-medication trial or starter-dose voucher for Zepbound or Mounjaro through official channels — the "starter kit" you may see referenced is educational material about beginning treatment, not free product. For actual free medication, the relevant program is Lilly Cares Foundation, the company's charitable patient-assistance arm.

Lilly Cares provides a free 12-month supply of Mounjaro to uninsured patients with a type 2 diabetes prescription whose household income falls at or below roughly 400% of the Federal Poverty Level. That's a meaningful program if you qualify on both counts. The honest gap: Zepbound is not currently on Lilly Cares' list of covered medications, so there is no equivalent free-medication pathway for weight management alone. Check lillycares.com directly before assuming otherwise — patient-assistance formularies do get updated.

Nothing here applies to you? The realistic next-cheapest route

Some women land outside every program on this page — insurance that excludes Zepbound entirely, no type 2 diabetes diagnosis for the Mounjaro card, and income too high for Lilly Cares. If that's you, the honest next step isn't full retail. Compounded tirzepatide through a telehealth provider, sold under a narrow individual-patient pathway, currently runs well below LillyDirect's self-pay tiers for most programs.

Annual math: what each program actually saves you over a year

A monthly number hides how much these programs diverge once you spread them across twelve months.

• Zepbound Savings Card ($25/fill, insured): roughly $300/year in what you pay — the card can save Lilly's insured patients up to $1,300/year off their plan's copay, but your out-of-pocket stays near $300.
• Mounjaro Savings Card ($25/fill, T2D): also roughly $300/year out of pocket, with up to $1,950/year in total savings versus an unsubsidized copay.
• LillyDirect self-pay, starter dose ($299/mo): about $3,588/year.
• LillyDirect self-pay, maintenance dose ($449/mo, on-time refills): about $5,388/year.
• GoodRx Zepbound (~$1,020/mo average, unconfirmed — see note above): about $12,240/year.
• GoodRx Mounjaro (~$1,045/mo average, unconfirmed — see note above): about $12,540/year.
• Lilly Cares (Mounjaro, income-qualified): $0/year for a 12-month supply.
• Retail, no discount at all (~$1,086/mo): about $13,032/year.

The gap that matters most: the savings card can be worth roughly $12,700 a year compared to paying retail — that's the single biggest lever on this page, if your insurance qualifies you for it. GoodRx's real-world savings on these particular brands are harder to pin down (see the unconfirmed pricing note above), but on any reading it's nowhere near the game-changer it is for generic drugs. Know which bracket you're actually in — and double-check the GoodRx number for your ZIP code — before you assume it's your answer.

Why the savings gap matters more in perimenopause

Weight gain in your forties and fifties often has a metabolic driver — shifting estrogen, worsening insulin resistance, fat redistribution toward the abdomen — that makes tirzepatide a genuinely different proposition than a discretionary cosmetic purchase for a lot of women. That reality doesn't change the math on this page, but it does raise the stakes of getting the cheapest legitimate route right, since this is often a long-term prescription, not a short course. A $12,000 annual gap between the savings card and full retail is the difference between a sustainable plan and one you abandon at month four.